We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA announced today it has approved Merck's Januvia (sitagliptin phosphate) Tablets, the first diabetes treatment approved in a new class of drugs known as DDP-4 inhibitors that enhances the body's own ability to lower elevated blood sugar.
A Swiss nongovernmental organization, the Berne Declaration,
has sent an open letter to Daniel Vasella, chairman and CEO of Swiss drugmaker Novartis, demanding that the company withdraw its legal actions against the Indian Patent Act and the rejection of its patent application for the cancer drug Gleevec (imatinib mesylate).
New Zealand's Pharmaceutical Management Agency (PHARMAC) has decided not to fund Roche's drug Herceptin for early stage breast cancer, the agency announced.
Schering-Plough Corporation announced that Fred Hassan, chairman and CEO, was named president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) at its biennial statutory meeting in Geneva.
Biotech company Pharming Group NV ("Pharming" or "the Company") today announced signing of the final Sale and Purchase Agreement and necessary corporate approvals to acquire DNage BV ("DNage").
AN estimated 7 million doses of malaria drugs in the custody of the National Medical Stores (NMS) might expire soon, NMS managers announced in Parliament.
Serono and Newron Pharmaceuticals SpA, announced today an agreement under which Newron has granted Serono exclusive worldwide rights to develop, manufacture and commercialise safinamide in Parkinson's disease (PD), Alzheimer's disease, and other cognitive disorders.
Teva Pharmaceutical Industries Ltd. announced today that patent infringement litigation pertaining to Teva's generic version of Purdue's OxyContin (oxycodone HCl extended-release) Tablets has been dismissed by the United States District Court for the Southern District of New York pursuant to a settlement between Teva and The Purdue Frederick Company and certain of its affiliates.
A new approach to treatment for pregnant women suffering from malaria in West Africa has been found to be both safe and effective, according to a randomized trial carried out by a team from the London School of Hygiene & Tropical Medicine (LSHTM) based in Ghana.